In this piece, we will take a look at the five newest additions to Cathie Wood’s latest stock portfolio. If you want to learn more about the hedge fund and its owner, head on to Cathie Wood Stock Portfolio: 7 Newest Stock Picks This Year.
5. COMPASS Pathways plc (NASDAQ:CMPS)
Ark Investment’s Stake Value: $4.1 million
Percentage of Ark Investment’s 13F Portfolio: 0.02%
Number of Hedge Fund Holders: 12
COMPASS Pathways plc (NASDAQ:CMPS) is a British healthcare company that is headquartered in London, the United Kingdom. The firm develops treatments for mental illnesses, and its COMP360 treatment has completed trials for the treatment of resilient depression and is currently undergoing trials for the treatment of complex post traumatic stress disorder.
Ark Investment bought 388,574 COMPASS Pathways plc (NASDAQ:CMPS) shares during this year’s third quarter, which allowed it to own a $4.1 million stake in the company. Insider Monkey’s Q2 2022 survey of 895 hedge funds revealed that 12 have also bought the company’s shares. Oppenheimer reduced its price target for COMPASS Pathways plc (NASDAQ:CMPS) to $55 from $65 in October 2022, as it stated that uncertainty surrounding filing requirements influenced the decision. However, the firm still has an Outperform rating for the shares.
COMPASS Pathways plc (NASDAQ:CMPS) is also financing seven other treatments for several diseases such as bipolar disorder, autism, and suicide ideation at different universities. Some of these universities include Columbia University, King’s College in London, and the University of Copenhagen.
COMPASS Pathways plc (NASDAQ:CMPS)’s largest investor in our database as of the second quarter is Christopher Medlock James’s Partner Fund Management which owns 392,764 shares that are worth $4.2 million.
4. Senti Biosciences, Inc. (NASDAQ:SNTI)
Ark Investment’s Stake Value: $4.5 million
Percentage of Ark Investment’s 13F Portfolio: 0.03%
Number of Hedge Fund Holders: 2
Senti Biosciences, Inc. (NASDAQ:SNTI) is a biotechnology company that develops gene therapies. These target diseases such as leukemia, carcinoma, and cancer cells. It is headquartered in South San Francisco, California.
Chardan Capital Markets set a $12 share price target for Senti Biosciences, Inc. (NASDAQ:SNTI) in September 2022, as it shared that the firm’s products can address several key concerns present with current gene therapies. The company’s latest earnings report saw it post $1.36 million in revenue for a strong 72% annual growth and -$0.86 in GAAP earnings per share.
Ark Investment’s third quarter investment portfolio saw the firm add two million Senti Biosciences, Inc. (NASDAQ:SNTI) shares which were worth $4.5 million. By the end of this year’s second quarter, two out of the 895 hedge funds polled by Insider Monkey had invested in the company.
3. XPeng Inc. (NYSE:XPEV)
Ark Investment’s Stake Value: $5.1 million
Percentage of Ark Investment’s 13F Portfolio: 0.03%
Number of Hedge Fund Holders: 24
XPeng Inc. (NYSE:XPEV) is a Chinese electric vehicle manufacturer that sells a variety of vehicles such as sports utility vehicles (SUVs), sports sedans, and family sedans. The company is headquartered in Guangzhou, the People’s Republic of China.
XPeng Inc. (NYSE:XPEV) is one of the primary players in China’s booming electric vehicle market which saw a record of 675,000 sales in September 2022. As of September end, the company had delivered 98,553 vehicles, which marked a 75% annual increase and surpassed the deliveries that it had made in the full calendar year 2021.
Ark Investment bought a $5.1 million stake in the company during this year’s third quarter. By the end of this year’s second quarter, 24 out of the 895 hedge funds polled by Insider Monkey had invested in XPeng Inc. (NYSE:XPEV).
Out of these, Chase Coleman and Feroz Dewan’s Tiger Global Management LLC is XPeng Inc. (NYSE:XPEV)’s largest investor. It owns 4.3 million shares that are worth $138 million.
2. Moderna, Inc. (NASDAQ:MRNA)
Ark Investment’s Stake Value: $19 million
Percentage of Ark Investment’s 13F Portfolio: 0.13%
Number of Hedge Fund Holders: 45
Moderna, Inc. (NASDAQ:MRNA) is an American biotechnology firm that uses messenger ribonucleic acid (RNA) technology to develop therapies for infectious diseases, heart diseases, cancer, and immune system disorders. The firm is headquartered in Cambridge, Massachusetts.
As this year’s third quarter ended, Ark Investment had bought 163,592 Moderna, Inc. (NASDAQ:MRNA) shares for a $19 million stake which represented 0.13% of its investment portfolio. Insider Monkey’s Q2 2022 survey of 895 hedge funds saw 45 as having invested in the firm.
Not only is Moderna, Inc. (NASDAQ:MRNA) responsible for manufacturing perhaps the most advanced coronavirus vaccine in the world, but the firm is also developing a cancer vaccine for melanoma patients with the pharmaceutical giant Merck and the firms expect to report data from trials during the ongoing quarter.
Moderna, Inc. (NASDAQ:MRNA)’s largest investor in our database is Patrick Degorce’s Theleme Partners which owns 6.3 million shares that are worth $907 million.
Baron Funds mentioned the company in its Q3 2022 investor letter. Here is what the fund said:
“Within biotechnology, underperformance of Moderna, Inc. (NASDAQ:MRNA) and lower exposure to this better performing sub-industry weighed the most on relative performance. Shares of Moderna, a leader in the emerging field of mRNA-based vaccines and therapeutics, declined due to increasing uncertainty around what a booster market could look like as COVID shifts away from pandemic status and becomes an increasingly commercial market rather than government funded.”
1. Guardant Health, Inc. (NASDAQ:GH)
Ark Investment’s Stake Value: $29 million
Percentage of Ark Investment’s 13F Portfolio: 0.2%
Number of Hedge Fund Holders: 35
Guardant Health, Inc. (NASDAQ:GH) is an American healthcare diagnostics firm. It offers services such as biopsy tests for cancer, blood tests, and the coronavirus. The firm is headquartered in Redwood City, California.
Cathie Wood’s investment firm bought 542,113 Guardant Health, Inc. (NASDAQ:GH) shares during the third quarter of this year, allowing it to hold a $29 million stake in the company. In the prior quarter, 35 out of the 895 hedge funds polled by Insider Monkey had invested in the company.
Guardant Health, Inc. (NASDAQ:GH)’s Guardant360 liquid biopsy test was approved by the Food and Drug Administration in August 2022. This test identifies lung cancer patients that can be treated with ENHERTU’s Enhertu cancer drug. The firm brought in $400 million revenue in June 2022, with the FDA approval providing more revenue opportunities.
Guardant Health, Inc. (NASDAQ:GH)’s largest investor in our database is Andreas Halvorsen’s Viking Global which owns 4.4 million shares that are worth $180 million.
Disclosure: None. You can also take a look at 10 Best LNG Stocks To Buy and 11 Best Cyclical Stocks To Buy.
